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Introduction: Decoding transcriptional effects of experimental tissue–tissue or cell–cell interactions is important; for
example, to better understand tumor–stroma interactions after transplantation of human cells into mouse
(xenografting). Transcriptome analysis of intermixed human and mouse cells has, however, frequently relied on the
need to separate the two cell populations prior to transcriptome analysis, which introduces confounding effects on
gene expression.
Methods: To circumvent this problem, we here describe a bioinformatics-based, genome-wide transcriptome
analysis technique, which allows the human and mouse transcriptomes to be decoded from a mixed mouse and
human cell population. The technique is based on a bioinformatic separation of the mouse and human
transcriptomes from the initial mixed-species transcriptome resulting from sequencing an excised tumor/stroma
specimen without prior cell sorting.
Results: Under stringent separation criteria, i.e., with a read misassignment frequency of 0.2 %, we show that 99 % of
the genes can successfully be assigned to be of mouse or human origin, both in silico, in cultured cells and in vivo. We
use a new species-specific sequencing technology—referred to as S3 (“S-cube”)—to provide new insights into the
Notch downstream response following Notch ligand-stimulation and to explore transcriptional changes following
transplantation of two different breast cancer cell lines (luminal MCF7 and basal-type MDA-MB-231) into mammary fat
pad tissue in mice of different immunological status. We find that MCF7 and MDA-MB-231 respond differently to fat
pad xenografting and the stromal response to transplantation of MCF7 and MDA-MB-231 cells was also distinct.
Conclusions: In conclusion, the data show that the S3 technology allows for faithful recording of transcriptomic
changes when human and mouse cells are intermixed and that it can be applied to address a broad spectrum of
research questions.Introduction
Genome-wide transcriptomic analysis provides import-
ant insights into many cellular processes, including
tumor development [1]. However, in many situations it
would be useful to simultaneously decode the transcrip-
tomes of two different interacting cell types; for example,
when human tumor cells are xenografted into mice. To
obtain the transcriptomic information from the trans-
planted cells and the surrounding stroma has, however,
frequently required physical separation of the human*Correspondence: urban.lendahl@ki.se
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this article, unless otherwise stated.and mouse cells (for example, by fluorescence-activated
cell sorting (FACS)-based separation using human- and
mouse-specific cell surface markers) and this extensive
handling of the cells prior to transcriptome analysis is likely
to affect the transcriptomic profiles. Alternatively, species-
specific quantitative real-time PCR (qPCR) analysis or
cross-species hybridization of microarrays have been
attempted [2, 3], but neither approach allows for a large-
scale probing of the transcriptomes from two species. It
would therefore be useful to develop new alternative
technologies that enable simultaneous high-throughput
analysis of human and mouse transcriptomes without
prior cell sorting.
In this report, we establish such a technology and ad-
dress two research questions in which human–mouseticle is distributed under the terms of the Creative Commons Attribution
mons.org/licenses/by/4.0/), which permits unrestricted use, distribution,
you give appropriate credit to the original author(s) and the source,
ense, and indicate if changes were made. The Creative Commons Public
ommons.org/publicdomain/zero/1.0/) applies to the data made available in
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naling and xenografting of human breast cancer cells
into mammary fat pads in mice. Notch signaling is an
evolutionarily highly conserved cell–cell signaling system
where a signal-sending cell expresses transmembrane li-
gands, such as Delta-like 4 (DLL4), that bind to the
transmembrane Notch receptor on a neighboring,
signal-receiving cell [4]. Thus, canonical Notch signaling
is often studied by activating Notch receptors through
co-culture of ligand- and receptor-expressing cells [5].
Because of the intermixing of ligand- and receptor-
expressing cells it has proven difficult to decode
transcriptional events specifically occurring in the
receptor-expressing cells. As deregulated Notch signal-
ing is linked to breast cancer, it is important from a
breast cancer perspective to better understand the tran-
scriptomic effects of Notch signaling. High levels of ex-
pression of Notch ligands or receptors have been often
correlated with poor prognosis [6, 7]. Gain-of-function
Notch mutations have been observed in breast tumors
[8] and the negative regulator Numb is frequently lost or
inactivated [9, 10]. Overexpression of activated forms of
Notch in mammary tissue in transgenic mice leads to
breast tumor development [11], and engrafting of hu-
man breast tumor cells with different levels of Notch
has revealed a role for Notch in tumor progression and
cellular metabolism [12]. Notch signaling is also impli-
cated in tumor–stroma interactions, metastasis and ther-
apy resistance in breast cancer [13–16].
Xenografting to the mammary fat pad is frequently
used to explore mammary stem and progenitor cell dif-
ferentiation [17] and to gain insights into growth and
metastasis of human breast cancer cell lines [18] and
patient-derived tumors [19]. Xenografting also provides
information about the stromal responses to the tumor
cells [20], which is important as the tumor–stroma
interplay has emerged as an interesting research area. It
is increasingly acknowledged that the stroma is not a
passive bystander in the tumor process, but that the
interplay between tumor and stroma is important for
tumor initiation, progression and metastasis [21, 22]. Xe-
nografting can also shed light on the differences between
different types of breast cancer cells. Breast cancer can
be classified into at least five different types [23], includ-
ing luminal and basal-type tumors. These two tumor
types differ with regard to prognosis, but also in terms
of how transplanted luminal and basal-type tumor cell
lines behave following transplantation in mice. Trans-
plantation of luminal cell lines, such as MCF7, result in
tumor formation but not metastasis, whereas transplant-
ation of the basal-type cell line MDA-MB-231 results in
both tumor growth and metastasis [24].
In this study, we develop a new bioinformatics-based
approach, which we refer to as S3 (S-cube; for species-specific sequencing) technology, which allows simultan-
eous analysis of mouse and human transcriptomes. We
demonstrate that the S3 technology can identify 99 % of
all genes to be of mouse or human origin at a low
species misassignment frequency, and we use the tech-
nology to provide new insights into transcriptional ef-
fects of Notch signaling and tumor–stroma interactions
in xenografts.
Methods
Cell lines and cell culture
MCF7 (ATCC®, HTB-22™) and MDA-MB-231 (ATCC®,
HTB-26™) human breast adenocarcinoma cell lines, 3T3-
L1 mouse embryonic fibroblast cell line (ATCC®, CL-
173™), 293T human embryonic kidney cell line (ATCC®,
CRL-3216™), and MCF7-EGFP [12, 25, 26] were cultured
in complete medium, composed of Dulbecco's modified
Eagle medium DMEM, high glucose, pyruvate (Gibco®,
cat. no. 41966-029) supplemented with 10 % fetal bovine
serum (Gibco®, cat. no. 10270-106) and 1 % penicillin-
streptomycin (10,000 U/mL, Gibco®, cat. no. 15140-122)
at 37 °C in a humidified 5 % CO2 atmosphere. Both MCF7
and MDA-MB-231 cells were cultured without estrogen
in the medium.
Plasmids
Pi2EGFP-hDLL4 [27] was generously donated by Prof.
Dr. Manfred Gessler (Biocenter of the University of
Würzburg, Germany). pCAGG-IRES-GFP and MH100-
HSP-lacZ were kindly donated by Prof. Johan Ericson
(Karolinska Institutet, Sweden). 12xCSL-Luc was a kind
gift from Dr. Tasuku Honjo (Kyoto University, Japan)
[28]. Fc-DLL4 was generously donated by Prof. Tom
Kadesch (University of Pennsylvania School of Medicine,
USA) [29].
Cellular co-culture analysis
We seeded 8.5 × 104 mouse 3T3-L1 cells per well in two
12-well plates in triplicate per sample group, and seeded
1.7 × 106 human MDA-MB-231 cells in one 100 mm dish.
Cells were allowed to settle, and were transfected the fol-
lowing day after the medium was changed to be antibiotic
free. 3T3-L1 cells were transfected with Pi2EGFP-hDLL4
or green fluorescent protein (GFP) (4 μg/well), using
Lipofectamine® 3000 (Invitrogen™, cat. no. L3000-015), ac-
cording to the manufacturer’s instructions. Six hours after
transfection, MDA-MB-231 cells were scraped and 8.5 ×
104 cells in 1 mL complete medium per well were added
to both 12-well plates. We added 20 μM N-[N-(3,5-
difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester
(DAPT; GSI-IX; 2 μL of 10 mM stock, Selleck Chemicals,
cat. no. S2215) per well to one plate, and added dimethyl
sulfoxide (DMSO; 2 μL, Sigma-Aldrich®, cat. no. D4540)
per well to the other as control. Cells were co-cultured for
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GEN, cat. no. 79216) with 1 % 2-Mercaptoethanol (Sigma-
Aldrich®, cat. no. M3148) and stored at –80 °C until RNA
extraction.
To measure Notch activity from the co-culture, a parallel
assay was set up as above, with the following modification:
MDA-MB-231 cells were co-transfected with 12xCSL-Luc
(30 μg/dish) and MH100-HSP-lacZ (3.0 μg/dish). Cells
were co-cultured for 18 hours, then lysed in 200 μL per
well luciferase lysis buffer (10 mM Tris pH 7.9, 300 mM
NaCl, 1.5 mM MgCl2, 0.65 % NP40), and stored at –20 °C
until luciferase assay was performed. Notch activity in cells
expressing the 12xCSL-Luc reporter construct was mea-
sured by a luciferase assay using the same reagents as de-
scribed [25, 26].
Activation of Notch signaling by immobilized ligand
We seeded 1.7 × 106 MDA-MB-231 cells per dish in one
100 mm dish. The following day, two 12-well plates were
coated with Fc control or Fc-DLL4, in triplicate per sam-
ple group, as previously described [30], with the follow-
ing modifications: Protein G (Pierce®, cat. no. 21193) 50
μg/mL in Dulbecco's phosphate-buffered saline (DPBS)
for 1 hour at room temperature, Fc-DLL4 conditioned
medium (approximately 1 μg/mL) [31] or ChromPure
Human IgG Fc fragment (Jackson ImmunoResearch
Laboratories, Inc., cat. no. 009-000-008) 1 μg/mL in 0.1 %
bovine serum albumin (BSA)-DPBS for 1 hour at room
temperature. MDA-MB-231 cells were scraped and 8.5 ×
104 cells in 1 mL complete medium per well were
added to both 12-well plates. We added 20 μM DAPT
(2 μL of 10 mM stock) per well to one plate, and added
DMSO (2 μL) per well to the other as control. Cells
were co-cultured for 6 hours, then lysed in 350 μL per
well Buffer RLT with 1 % 2-Mercaptoethanol, and
stored at –80 °C until RNA extraction.
To measure the Notch activity by immobilized ligand
activation, a parallel assay was set up as above, with the
following modification: MDA-MB-231 cells were co-
transfected with 12xCSL-Luc (30 μg/dish) and MH100-
HSP-lacZ (3.0 μg/dish). Cells were seeded on coated
plates for 18 hours, then lysed in 200 μL per well lucifer-
ase lysis buffer and stored at –20 °C until luciferase
assay was performed. Luciferase activity was analyzed as
described above.
Tumor and mammary gland extraction
For MCF7 tumors, 2 × 106 MCF7-EGFP cells were
mixed with BD Matrigel™ Basement Membrane Matrix
(BD Biosciences, cat. no. 356234) and injected into the
left and right cleared fourth inguinal mammary fat pads
of two female athymic Nude-Foxn1nu mice (Harlan
Laboratories). The tumors were allowed to grow for 8
weeks, supplemented with estrogen and progesteronepellets (Innovative Research of America) to support
growth. Tumors were excised upon reaching a volume
of 500 mm3, immersed in RNALater solution (Ambion®,
cat. no. AM7020), and stored at –80 °C.
For MDA-MB-231 tumors, 2 × 106 MDA-MB-231
cells in 50 μL phosphate-buffered saline (PBS) were
injected into the left intact fourth inguinal mammary fat
pad of four female Fox Chase SCID® Congenic-CB17/
Icr-Prkdcscid/IcrIcoCrl mice (Charles River Laboratories,
strain code 236). The tumors were considered to be
established when the largest diameter exceeded 3 mm.
The established tumors were excised after approximately
4–5 weeks at an average volume of 500 mm3 (tumor
volume = π/6 × length × width2). Mice were injected
with 2.5 % Avertin, heart-perfused with 10 mL PBS, and
tumors resected. Tumors were snap-frozen by a dry ice/
ethanol slurry, and stored at –80 °C. These tumors were
obtained from mice in the control group of another ex-
periment, and were treated with IgG antibody twice a
week for a total of eight times.
As control, the left fourth mammary gland of a female
NSG-NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mouse (Jackson La-
boratories, strain 005557) was cleared, dissected, immedi-
ately preserved in RNALater solution, and stored at –80 °C.
Homogenization, RNA extraction and cDNA library
preparation
Homogenization of MCF7 and MDA-MB-231 tumors was
performed by the “Lysis and Homogenization: 10–100 mg
Frozen or Fresh Fibrous Tissue, Mortar and Pestle Proto-
col” of the PureLinkTM RNA Mini Kit (Ambion®, cat. no.
12183-018A). Homogenization of the thawed mouse
mammary gland was performed by mincing the tissue in
200 μL TRIzol® Reagent (Ambion®, cat. no. 15596-026)
with a scalpel, using an RNase/DNase-free pestle and 1.5
mL tube to dissociate larger pieces in solution, and pass-
ing tissue solution through a 23-gauge needle ten times.
RNA extraction for all cell lysates from the immobilized
ligand assay, two-species co-culture, MCF7 cells and
MDA-MB-231 cells was performed using the RNeasy
Mini Kit (QIAGEN, cat. no. 74104). RNA extraction of
homogenized MCF7 and MDA-MB-231 tumors was per-
formed using TRIzol Reagent followed by purification
using the PureLink RNA Mini Kit. RNA extraction of the
homogenized mammary gland was performed using TRI-
zol Reagent and PureLink® DNase (Ambion®, cat. no.
12185010) treatment. RNA concentration and RNA integ-
rity number (RIN) were calculated by an Agilent 2100
Bioanalyzer system using the Agilent RNA 6000 Nano Kit
(Agilent Technologies Inc., cat. no. 5067-1511).
cDNA libraries for all samples were created using the
TruSeq® RNA Sample Prep Kit v2–48, Set B (Illumina®,
cat. no. RS-122-2002), as per the TruSeq® RNA Sample
Preparation v2 Guide, Low-Throughput Protocol. The
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100 ng per sample of cell lysates, 200 ng of mammary
gland, and 1 μg per sample of MCF7 and MDA-MB-231
tumors. Quantification and quality control of the cDNA
libraries was performed using the Agilent DNA 1000 Kit
(Agilent Technologies Inc., cat. no. 5067-1504). Quanti-
fication of pooled libraries was performed using the
Qubit® 2.0 Fluorometer (Invitrogen™, cat. no. Q32866)
and Qubit® dsDNA HS Assay Kit (Invitrogen™, cat. no.
Q32851), and concentration of pooled libraries was di-
luted to 2 nM. All kits were used as per the manufac-
turer’s instructions.
Alignment and analysis of technical performance
The cDNA libraries were sequenced on a HiSeq 2000 with
a 50–52 read length, single-end, for different samples. The
reads were aligned to both the human genome (assembly
hg19) and the mouse genome (assembly mm10) using
STAR [32] with default settings (e.g., 10 mismatches max-
imum) in the version from 11 Feb 2013. For each species,
we filtered for reads that had a unique match to that spe-
cies' genome (quality score 255) and did not align to the
other species' genome. For technical comparison in some
analyses we also kept a set of aligned reads which mapped
uniquely but without the filter for the other species gen-
ome. We also aligned reads using Bowtie [33] with the
setting -best to both genome and transcriptome (from
Ensembl for mouse, GENCODE for human), for compari-
son of alignment performance. We then calculated gene
expression values using rpkmforgenes.py [34] (with the
settings -rmnameoverlap -bothendsceil and RefSeq anno-
tation downloaded 1 Jul 2014 from the UCSC genome
browser). We removed microRNA and snoRNA genes
since they had had extreme variability in previous projects,
plus they are not normally polyadenylated, and applied
TMM (trimmed mean of M-values) normalization of the
RPKM values. Using only the reads mapping to the pro-
tein coding transcripts, we calculated the read losses due
to ambiguous mapping as reads mapping to both species
divided by reads mapping to the species of origin (Fig. 1b).
The definition of “full loss” genes is the number of genes
going from non-zero to zero expression upon discarding
multi-species mapping reads, whereas the “partial loss”
genes are those getting fewer reads but still non-zero.
Since the true origin of each sequence was known, we
could also calculate the number of misassigned reads
(Fig. 1c). The samples in the in-silico analysis were three
human samples from [35] (H1-3), three mouse samples
(M1-3) [36], mbrNoAmp-s_1 (M4) and mbrNoAmp-s_2
(M5) [37] and the rat samples SRR1586060 (R1) [38],
SRR1613356 (R2) [39] and ERR530739 (R3) [40]. Raw
sequence reads have been deposited at the NCBI Se-
quence Read Archive (SRP056041) and processed gene ex-
pression values at the NCBI Gene Expression Omnibus(GSE66744). The detected gene cutoff was set to 1 read
and the fold changes added a pseudo-value of 0.3 RPKM
(based on the background value in Ramsköld et al. [41])
before calculating the ratio. For Xenome, we used the
graft and host output files and aligned the reads with
STAR using the default settings.
Statistics and additional bioinformatics
For the figures showing principal component analysis, we
used the prcomp function in R. We used DAVID func-
tional annotation tool for a Gene Ontology enrichment
analysis [42, 43], taking one term from each cluster in the
output and requiring a 5 % Benjamini-adjusted p-value
produced by DAVID. Because a maximum of 3000 genes
can be analyzed using the official gene symbol identifier, a
random number generator was used to choose 3000 genes
from lists containing greater than 3000 genes. For differ-
ential expression testing we reused a test from Ramsköld
et al. [37], but modified to take RPKM values as input in-
stead of exon inclusion frequency. This test used the same
statistic as in significance analysis of microarrays (SAM),
and then p-values were calculated by permuting the sam-
ples to create a null distribution, and produced false
discovery rates (FDRs) using the Benjamini-Hochberg
method. The complete script for the S3 technology (from
fastq.gz file input to final human/mouse gene expression
quantification output) is given in [44]. Fisher’s exact test
was deployed to test gene list overlap, using 24,112 as the
total number of human genes and 23,225 as the total
number of mouse genes, and the values are presented in
Additional file 1 (Table S1). The p-value tables from SAM
(see above) are listed in Additional file 2 (Table S2).
Luciferase assay comparisons in Figs. 2b and 3b were ana-
lyzed using two-tailed unpaired Student’s t-test with
Welch’s correction. The genes corresponding to the gene
counts in figure panels of in vitro comparisons (Fig. 3e;
Additional file 3: Figure S4 and Additional file 4: Table S3)
are listed in Additional file 5 (Table S4).
Statement of ethical approval
Animal experiments were conducted in accordance with
the institutional animal care policies of Karolinska Institu-
tet, University of Turku and Åbo Akademi University.
Stockholms Norra Djurförsöksetiska granted ethical permit
number N151/14. The Finnish animal ethics committee
granted ethical permit numbers STH471A/ESLH-2008-
05395/Ym-23 7.7 2009, STH169A/ESLH-2009-01942/Ym-
23 11.3 2009, and ESLH-2008-05395/Ym-23 23.6 2011.
Results
Species-specific sequencing—separation of mouse and
human transcriptomes in silico
We wanted to establish a technology that faithfully reports


























































































































Fig. 1 Species-specific sequencing—separation of mouse and human transcriptomes in silico. a Schematic flowchart of the principle steps in the
S3 technology. A specimen of mixed human and mouse cells (for example, from a tumor–stroma xenograft experiment) is subjected to RNA-seq.
The mixed transcriptome is bioinformatically separated into human and mouse transcriptomes, discarding transcripts with a defined maximum
number of mismatches. b Fraction of reads that are species-ambiguous; i.e., cannot be assigned only to one species and therefore discarded. c
Fraction of misassigned reads; i.e., species-specific reads that align to mouse genes for human samples or to human genes for mouse samples.
Data in b and c are from three human (79 bp reads, in blue) and three mouse (51 bp reads, in pink) samples. d Percentage of expressed genes
with full (orange) or partial (purple) loss of reads after S3 in the three human (H1–3) and mouse (M1–3) samples. e Scatterplot and Spearman
correlation between a mouse sample (M1) and mouse expression values from S3 applied to a mix of human (H1) and mouse (M1) samples. f
Spearman correlations for the human (blue) and mouse (pink) S3 components of in silico mixes of H1 + M1, H2 + M2 and H3 + M3. g The
number of reads assigned by S3 as human, mouse or rat for three rat samples, normalized by the number of rat reads
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to align all sequence reads and discard the overlaps and a
flowchart for the principle steps in the S3 technology is
presented in Fig. 1a, with a program-by-program presen-
tation available as Additional file 3 (Figure S1). We began
our analysis by first exploring to what extent transcrip-
tomes of mouse and human origin could be separated in
silico. We set up a pipeline where RNA-seq data were
aligned to both the mouse and human genomes by the
program STAR, removing reads that aligned to both. We
have optimized the settings for this pipeline (Additional
file 6: Table S5), finding that the settings -Mu 1 (max. 1mismatch for unique) -Ms 1 (max. 1 mismatch for
shared) -D 2 (max. 2 mismatch difference) gave the
best balance between sensitivity and specificity. The
code is available at [44]. We tested this pipeline on
three human (79 bp reads) and three mouse (51 bp
reads) samples and found that, on average, 9.8 % of the
reads were discarded as species-ambiguous (Fig. 1b)
and that, on average, 0.2 % of the reads were assigned
to the wrong species (Fig. 1c). The discarded reads cor-
responded to a full loss of, on average, 0.9 % of the
expressed genes (all reads lost) and a partial loss of 1.9 %
of the expressed genes (some reads lost) (Fig. 1d). The
Fig. 2 Analysis of ligand-induced Notch signaling using S3 technology. a Schematic depiction of the co-culture system used to analyze the Notch
downstream response. The human MDA-MB-231 cells express robust levels of the Notch1 receptor and are co-cultured with mouse 3T3-L1 cells,
which in some experiments are transfected with the Delta-like 4 (DLL4) ligand. b Analysis of 12xCSL-Luc activity for various combinations of
co-culture of 3T3-L1 and MDA-MB-231 cells, where the latter are transfected with the Notch reporter 12xCSL-Luc. Note the increase in reporter
activity where 3T3-L1 cells transfected with the DLL4 ligand are co-cultured with MDA-MB-231 cells, and that this increase is abrogated by the addition
of N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT). Relative luciferase units (RLU) were normalized to beta-galactosidase values
before fold change analysis. *p < 0.05, **p < 0.01 (Student’s t-test). Replicates per treatment group (n = 3) are from one culture split prior to transfection
and measurement. c Fold change of expression levels (RPKM) for four genes (GPR1, MTHFS, SGK3 and NME2) from MDA-MB-231 cells co-cultured with
3T3-L1 cells transfected with DLL4 or green fluorescent protein (GFP) in the presence (+DAPT) or absence (-DAPT) of DAPT, as indicated. d Principal
component analysis (PCA) of the genome-wide transcriptomes in MDA-MB-231 cells in response to DLL4 ligand-stimulation and DAPT treatment, as
described in the figure. e Expression levels of human DLL4 in the co-cultures of MDA-MB-231 and 3T3-L1 cells, as described. Note the high level of DLL4
expression in cells transfected with a human DLL4 plasmid (the two bars to the right, light green)
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2500 genes on average; i.e., they contribute to a low
background level of expression, although genes for nu-
clear proteins tended to have more such reads than
other genes (Additional file 7: Table S6A). To ascertain
that species misassignment and potential biases in read
loss does not cause S3 expression values to lose accur-
acy, we mixed pairs of human and mouse samples in
silico and compared expression values before and after
mixing the samples and using S3 (Fig. 1e,f ), with good
correlation. As recent reports have described related
technologies to decode mixed-genome transcriptomes
[45, 46–48], we directly compared our method to one
of these methods, Xenome, for which a detailed scriptis available [45]. The comparison revealed that the S3
technology has 1.6 ± 0.2 (SEM) times better separation
between species and retains 4.8 ± 0.5 times more reads
as compared to Xenome combined with STAR align-
ment (Additional file 3: Figure S2).
We next asked whether the S3 technology would be able
to cope with a comparison of transcriptomes from more
than two species, which would be useful for example
when human tumor cells and rat cancer-associated fibro-
blasts (CAFs) are xenografted into the mouse to study
specific aspects of tumor–CAF interaction. When we
aligned rat samples to three genomes—mouse, human
and rat—and separated the reads by species with S3,
we noticed large numbers of reads being assigned as
Fig. 3 (See legend on next page.)
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Fig. 3 Analysis of two different modes of Notch ligand presentation. a Schematic depiction of activation of Notch by immobilized ligand (Fc-DLL4) or
with Fc as control. b Analysis of 12xCSL-Luc activity in MDA-MB-231 cells cultured on immobilized Fc-DLL4 or Fc alone as control, and in the presence
or absence of N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT), as indicated. Note the increase in reporter activity when cells
are cultured on Delta-like 4 (DLL4) and that this activity is abrogated by the addition of DAPT. Relative luciferase units (RLU) were normalized to
beta-galactosidase values before fold change analysis. *p < 0.05, **p < 0.01 (Student’s t-test). Replicates per treatment group (n = 3) are from one
culture split prior to transfection and measurement. c Fold change of expression levels (RPKM) of four genes (P2RY11, MOB4, FAM183A and PRSS22) in
the MDA-MB-231 cells in response to DLL4 ligand-stimulation and DAPT treatment, as described in the figure. d Principal component analysis (PCA) of
the genome-wide transcriptomes in MDA-MB-231 cells in response to DLL4 ligand-stimulation and DAPT treatment, as indicated. e Comparison of
Notch response signatures derived by DLL4 presented from co-cultured cells (left) or immobilized DLL4 (right). In the upper left circle are the 164 genes
that are >2-fold upregulated in MDA-MB-231 cells by DLL4 on 3T3-L1 cells and the lower left circle denotes the 164 genes that are downregulated by
DAPT. The overlap between these two categories (63 genes) are genes that are both upregulated by DLL4 and downregulated by DAPT, i.e. the Notch
signature. For the immobilized ligand there are 76 genes that are upregulated by immobilized DLL4, and 84 genes are downregulated by DAPT. The
overlap is 29 genes, which are both upregulated by immobilized DLL4 and downregulated by DAPT. Comparison of the “co-culture” and “immobilized”
signatures identifies only one gene in common (the middle section of the figure). *p < 0.05 (Fisher’s exact test). f Fold change of expression levels
(RPKM) from four well-established Notch target genes (NRARP, HES4, HES1 and SNAI1) in the MDA-MB-231 cells in response to DLL4 ligand-stimulation
by co-culture (upper row) or DLL4 immobilized ligand (immob. lig., lower row), respectively, and in the presence or absence of DAPT as indicated. GFP
green fluorescent protein
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mouse samples (Additional file 3: Figure S3), and we
suspect the difficulty lies with gaps and/or incorrect
sequence in the rat genome assembly, which currently
has a much lower quality than the mouse and human
genome assemblies. In conclusion, the in silico ana-
lysis provides proof-of-concept that species-specific
differences can be effectively used to dichotomize a
mixed-species transcriptome, and the technology can
also be extended to analyze more than two species, in
particular where high-quality genome information is
available.
Analysis of ligand-induced Notch signaling using S3
technology
We used the S3 technology to gain further insights into
Notch signaling and, more specifically, to assess whether
the mode of Notch ligand presentation to Notch receptor-
expressing cells affects the Notch downstream response.
Notch signaling starts when a Notch ligand (such as
DLL4) on one cell interacts with a Notch receptor on a
neighboring cell leading to γ-secretase complex-mediated
proteolytic processing of the Notch receptor, ultimately
releasing its intracellular domain (Notch ICD). Notch ICD
then translocates to the nucleus, where it binds to the
DNA-binding protein CSL (RBP-Jκ) to activate transcrip-
tion of downstream genes (for reviews see [4, 49]). To
study receptor activation, there are two principally differ-
ent ways to activate Notch signaling by ligand: the ligand
can be expressed on a neighboring cell or immobilized
in the culture dish. To what extent these two ways of
providing ligand yields different responses is not
known, as it has been difficult to establish a genome-
wide transcriptome in the Notch receptor cells in the
co-culture situation because of confounding effects of
the ligand-presenting cells.To induce Notch signaling we co-cultured mouse em-
bryonic fibroblast 3T3-L1 cells transiently transfected
with human DLL4 plasmid (3T3-L1DLL4) or GFP plas-
mid (3T3-L1GFP) as control, with human breast adeno-
carcinoma MDA-MB-231 cells, which express robust
levels of the Notch1 receptor [31, 50] (schematically
depicted in Fig. 2a). Activation of Notch signaling after
ligand stimulation was verified by upregulation of the
transfected Notch reporter 12xCSL-Luc in the MDA-
MB-231 cells after 18 hours of co-culture with the
DLL4-expressing cells, and this activation was abrogated
by the γ-secretase inhibitor DAPT (Fig. 2b). Analysis of
the transcriptome of all combinations of the 3T3-L1 and
MDA-MB-231 cells revealed that more than 98 % of
expressed genes could be distinguished in both human
and mouse transcriptomes (Additional file 8: Table S7, %
remaining genes), in keeping with the in silico sorting re-
sults presented above. The proportion of human and
mouse sequence reads was close to 50 % (Additional file
8: Table S7C, % reads), indicating that there were approxi-
mately equal numbers of MDA-MB-231 and 3T3-L1 cells
in each co-culture experiment. In our single-species sam-
ples, we observed that 0.1–0.3 % reads were assigned to
the wrong species (Additional file 8: Table S7, % reads),
due to sequencing read errors, which normally occur at
this frequency in RNA-Seq [51, 52]. We next compared
the MDA-MB-231 transcriptomes derived after exposure
to 3T3-L1DLL4 or 3T3-L1GFP cells. Co-culturing with the
3T3-L1DLL4 cells upregulated 164 genes and downregu-
lated 415 genes as compared to co-culturing with the
3T3-L1GFP cells (Additional file 3: Figure S4A).
We next analyzed the effect of blocking Notch signal-
ing by the γ-secretase inhibitor DAPT, which abrogates
Notch receptor cleavage [49]. Addition of 20 μM DAPT
at the onset of the co-culturing (i.e., for a total of 6
hours) resulted in downregulation of 63 of the 164 genes
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expressing cells (Additional file 3: Figure S4A). A num-
ber of genes, such as GPR1, MTHFS, SGK3 and NME2,
showed very strong DAPT-mediated abrogation of the
DLL4-induced activation (Fig. 2c) but, at the genome-
wide transcriptome level, DAPT only caused a partial re-
sponse, as visualized in the principal component analysis
(PCA) in Fig. 2d. This may be a consequence of the
DAPT treatment being too short to completely eradicate
Notch signaling (e.g., some Notch1 ICD present at the
start of the 6-hour DAPT blockade could linger on and
still exert a gene-inducing effect after 6 hours). The tran-
scriptome data showed very high expression of human
DLL4 in the 3T3-L1DLL4 cells in both the absence and
presence of DAPT (Fig. 2e), indicating that transfection
of DLL4 was successful and that DLL4 expression was
not affected by γ-secretase inhibition. The whole-
genome gene expression quality control (QC) data,
demonstrating good sequencing depth saturation, are
presented in Additional file 3 (Figure S5) and the whole-
genome gene expression QC density plots are shown in
Additional file 3 (Figure S6).
To compare the data from DLL4 presented on neighbor-
ing cells with a Notch transcriptome resulting from immo-
bilized DLL4 ligand, we cultured MDA-MB-231 cells on
Fc-DLL4 ligand for 6 hours (schematically depicted in
Fig. 3a). The 12xCSL-Luc reporter construct was, as ex-
pected, robustly activated by immobilized DLL4, as com-
pared to exposure to Fc fragment alone (Fig. 3b).
Culturing on Fc-DLL4 ligand upregulated 76 genes,
whereas 127 genes were downregulated (Additional
file 3: Figure S4B). Of the 76 upregulated genes, 29
were downregulated by DAPT treatment for 6 hours
(Additional file 3: Figure S4B). As for the induction of
Notch signaling by DLL4 in co-culture, a number of
genes, such as P2RY11, MOB4, FAM183A and
PRSS22, showed robust upregulation by DLL4 and an
almost complete downregulation by DAPT (Fig. 3c)
but, at the genome-wide level, the DAPT blockade of
the immobilized DLL4 was incomplete, although more
effective than in the co-culture setting (PCA; Fig. 3d).
To compare the “co-culture” and “immobilized” DLL4
transcriptomes we first decoded a Notch transcriptomic
signature in both settings, as defined by all genes that
were upregulated by DLL4 ligand and where the upregu-
lation was reduced by DAPT treatment (Fig. 3e); 63
genes met these criteria in the “co-culture” setting,
whereas 29 genes were upregulated by immobilized
DLL4 ligand and downregulated by DAPT. Interestingly,
when these two gene sets were cross-compared, only
one gene was common to both the “co-culture” and
“immobilized” Notch signatures (Fig. 3e; Additional file
4: Table S3A-B, PCA Additional file 3: Figure S7A). This
indicates that the mode of ligand presentation isimportant for the transcriptional response. A compari-
son of the genes activated in MDA-MB-231 cells by co-
culturing with 3T3-L1GFP cells or cultured alone on Fc
using Gene Ontology yielded several genes associated by
an inflammatory and cytokine response that were upreg-
ulated only by co-culturing (Additional file 7: Table S6B,
Additional file 4: Table S3C, PCA Additional file 3:
Figure S7B). In line with differential responses to the
mode of ligand presentation, the transcriptional re-
sponses for the Notch target genes NRARP, HES4, HES1
and SNAI1 [30, 53] were to some extent different in the
“co-culture” or “immobilized” settings (Fig. 3f ).
Finally, analysis of the transcriptomic changes in the
ligand-presenting cells (i.e., the 3T3-L1 cells) revealed
that 245 genes were uniquely upregulated and 371 genes
downregulated in the DLL4-expressing cells as com-
pared to GFP-expressing 3T3-L1 cells (Additional file 3:
Figure S4C, PCA Additional file 3: Figure S7C). Of the
245 genes, 98 were sensitive to DAPT treatment
(Additional file 3: Figure S4C). Overall, these data show
that the S3 technology can be used to faithfully report
mouse and human transcriptomes from co-cultured
cells, and also provide novel insights into the Notch
downstream response with regard to different modes of
ligand presentation.
Transcriptional consequences of xenografting luminal and
basal-type breast tumor cell lines in mice
Xenografting tumor cells into mammary tissue in mice
has yielded important information about breast tumor
growth in vivo [24, 54, 55], but it has been difficult to
simultaneously obtain a genome-wide understanding of
transcriptome changes in both tumor and stroma. We
therefore decided to use the S3 technology to address: 1)
how the transcriptomes of luminal (MCF7) and basal-
type (MDA-MB-231) transcriptomes change upon trans-
plantation to mammary tissue in mice; and 2) how the
surrounding stroma is affected by transplantation of the
two cell types. We also used different modes of trans-
plantation: MDA-MB-231 cells were transplanted dir-
ectly into the mammary fat pad whereas MCF7 cells
were grafted into cleared fat pads. The immune status of
the recipient mice was likewise different: nude mice
were used for the MCF7 transplantations, whereas SCID
mice were used for MDA-MB-231 transplantations.
MCF7 or MDA-MB-231 cells were transplanted and the
human (tumor) and mouse (stroma) transcriptomes
from excised combined tumor and stroma were bioinfor-
matically separated (see Fig. 1a). The percentage of hu-
man sequence reads in the analyzed mixed-species
samples of xenografted MCF7 cell/stroma specimens
ranged from approximately 25 to 75 %, while xeno-
grafted MDA-MB-231 cell/stroma specimens had ap-
proximately 80–90 % human reads (Additional file 8:
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anced proportion of tumor and stroma (one sample,
Mouse1R_MCF7-EGFP that contained less than 5 %
tumor or stroma contribution, was discarded and not
used for further analysis). The whole-genome gene ex-
pression QC data demonstrate that there is good se-
quencing depth saturation (Additional file 3: Figure S5).
The whole-genome gene expression QC density plots
are shown in Additional file 3 (Figure S6). For the MCF7
cells, 2142 genes were upregulated and 1564 genes were
downregulated in the xenograft situation as compared to
in vitro cultured cells (Additional file 9: Table S8A). The
xenograft and in vitro cultured MCF7 transcriptomes
clustered separately as judged by PCA, and the spread
among the xenograft samples was larger (Additional file
3: Figure S7D), probably reflecting a larger individual
variation in the tumor situation. Of note, the MCF7 cells
were not grown with estradiol supplementation in vitro
to mimic the estrogen and progesterone pellets utilized
for the xenografting, but genes involved in estrogen sig-
naling do not look to be over-represented in the MCF7
tumor samples compared to MCF7 cells (Additional file
3: Figure S8) [56, 57, 58].
For the basal-type MDA-MB-231 cells, 1456 genes were
upregulated and 897 genes downregulated in the xeno-
graft compared to the in vitro culturing (Additional file 9:
Table S8A). Gene Ontology analysis demonstrated that
genes upregulated in xenografted MDA-MB-231 showed
an enrichment of genes involved in cell adhesion
(Additional file 7: Table S6C). PCA also revealed that the
MDA-MB-231 transcriptomes from in vitro culturing
clearly segregated from the xenograft transcriptomes
(Additional file 3: Figure S7E). A comparison of the 2142
and 1456 genes upregulated in MCF7 and MDA-MB-231
cells after xenografting, respectively, showed that only 324
genes were upregulated in both cell types (Fig. 4a) and
131 genes were downregulated (Fig. 4b), suggesting dis-
tinctly different adaptation needs for the two cell lines
upon being xenografted. An analysis cut-off of fold-
change (>2-fold), rather than FDR (<5 %), was used since
sample numbers between comparison groups were not
similar (Additional file 9: Table S8).
On the stromal side, a large number of genes were up-
or downregulated in the stroma when MCF7 or MDA-
MB-231 cells were transplanted, as compared to
untransplanted mammary gland (Additional file 9: Table
S5B). For all comparisons presented in Table S8, scatter-
plots (Additional file 3: Figure S9) show the differentially
expressed genes are not lowly expressed, indicating that
the cutoff of 0.3 RPKM successfully removed “noisy”
genes from the analysis. When the MCF7 stromal
transcriptome was directly compared to the stroma
surrounding MDA-MB-231 cells we identified 4394
genes upregulated in the MCF7 versus the MDA-MB-231 stroma, whereas 743 genes were downregulated
(Additional file 9: Table S8B). Using only in vivo data,
PCA clustered the individual MCF7 and MDA-MB-231
stroma experiments separately and they were also well
separated from the untransplanted mammary gland
transcriptome, with MCF7 clustering roughly midway
(considering the greater importance of PC1 over PC2)
between the untransplanted experiment and the MDA-
MB-231 stroma (Fig. 4c). This predicts a smaller gene
overlap between MDA-MB-231 stroma and untrans-
planted mammary gland than between MCF7 stroma
and untransplanted mammary gland; this was indeed ob-
served when comparing the overlap among upregulated
(>2-fold) or downregulated genes (>2-fold) against the
third group (Fig. 4d-e), especially among upregulated
genes (Fig. 4d). Gene Ontology analysis of the stromal
transcriptomes revealed that the MDA-MB-231-induced
stromal transcriptome was over-represented with re-
gard to genes involved in blood vessel morphogenesis
(Additional file 7: Table S6D). In the MCF7-induced
stromal gene set, genes involved in chromatin modifi-
cation were found (Additional file 7: Table S6D). An
unsupervised hierarchical clustering of all human and
mouse transcriptomes from both the in vivo and
in vitro analysis and the different transcriptomes
showed the expected clustering (Additional file 3:
Figure S10). Finally, we investigated the expression of a
published list of universal stromal markers [59], and
could confirm that it indeed reflected the stromal
response to a tumor, for both the MCF7 and the MDA-
MB-231 xenografts (Additional file 3: Figure S11).
Discussion
In this report, we describe a bioinformatics-based ap-
proach to simultaneously decode the transcriptomes of
mixed-species samples without tissue handling and phys-
ical separation of the cells. The sorting of the mRNAs to
human or mouse origin is based on sequence differences
in the coding regions and, under stringent conditions (i.e.,
with a read misassignment frequency of 0.2 %), on average
99 % of all genes could be assigned as either mouse or hu-
man, both in silico, in vitro and in vivo. Four recent stud-
ies describe similar approaches to bioinformatically sort
human and mouse transcriptomes [45, 46–48], but with
some noticeable differences in how mismatches are used.
In particular, S3 makes use of the difference in the number
of mismatches for a read. A direct comparison with the
Xenome strategy [45], which like the S3 technology pro-
vides a user-friendly code, revealed that the S3 technology
has better species separation and better read retention. Al-
though all these studies have focused on the separation of
mouse and human transcriptomes, the technology can in
principle be applied to more than two species, and we
provide an example from a comparison of human, mouse
Fig. 4 Transcriptional consequences of xenografting MCF7 and MDA-MB-231 cells into mammary fat pads in mice. a,b Venn diagrams comparing
MCF7 and MDA-MB-231 transcriptomes in vitro and in vivo. a The overlap (324 genes) between the 2142 genes that are upregulated in MCF7
tumors vs. in vitro culturing (left) and the 1456 genes that are upregulated in MDA-MB-231 tumors vs. in vitro culturing (right). b Similar analysis as
in a, but for genes downregulated in MCF7 and MDA-MB-231 tumors as compared to in vitro culturing. c Principal component analysis (PCA) of
untransplanted mammary gland, MCF7 tumor stroma (top to bottom: 3R, 1L, 3L) and MDA-MB-231 tumor stroma (top to bottom: 1, 32, 13, 22). d
The number of genes upregulated (fold change (FC) >2) in MCF7 tumor stroma compared to MDA-MB-231 tumor stroma, as a subset of the
number of genes upregulated in MCF7 or MDA-MB-231 tumor stroma compared to untransplanted mammary gland. e The number of genes
downregulated (FC >2) in MCF7 tumor stroma compared to MDA-MB-231 tumor stroma, as a subset of the number of genes downregulated in
MCF7 or MDA-MB-231 tumor stroma compared to untransplanted mammary gland. *p < 0.05 (Fisher’s exact test)
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complete characterization of the rat genome likely re-
duced the specificity. Furthermore, the degree to which
the two mRNA populations can be bioinformatically sepa-
rated will depend on the extent of evolutionary distance
between the two species but the strategy can in fact be
used to provide important information also from very
closely related genomes. Recently an intercross between
Mus musculus domesticus and Mus musculus castaneus
was used to unravel the transcriptional profiles in preim-
plantation mouse development, and the difference be-
tween these two mouse subspecies was sufficient to
decode the transcriptional contribution from the maternal
and paternal genomes [60].
We used the S3 technology to explore whether the
mode of ligand presentation affected the Notch down-
stream response. While a synthetic Notch reporter con-
struct and a number of classical Notch target genes,
such as Nrarp, Hes1 and Snail, were activated by both
immobilized ligand and ligand presented on co-cultured
cells, the genome-wide transcriptional profiles were
quite distinct. In fact, only one gene was identified that
in both settings was upregulated by DLL4-ligand and the
ligand-mediated upregulation abrogated by DAPT. The
reasons for this difference between the “co-culture” and
“immobilized” Notch signatures remains to be further
explored. The short time window for activation (i.e., 6
hours of ligand stimulation) may lead to differences if
genes have different temporal activation profiles in the
two settings. Furthermore, as the PCA data indicate, the
6-hour DAPT treatment may be insufficient to eradicate
all Notch signaling. It is also possible that in the co-
culture situation production of secreted factors from the
ligand-expressing cell may synergize with Notch ligand
activation to govern gene expression, which may at least
in part explain the difference between the “co-culture”
and “immobilized” Notch signatures. In summary, as
both immobilized ligand stimulation and presentation of
ligand from juxtaposed cells in co-culture are methods
frequently used to activate Notch signaling (for example
in breast cancer research) it may be important to keep
in mind that the two modes of ligand presentation may
yield partly different responses.
The importance of the interaction between tumor and
stroma is increasingly recognized [21, 22] and we show
that the S3 technology can be productively used to decode
the tumor and stroma transcriptomes from mammary fat
pad xenograft experiments. Our data demonstrate that
both the MCF7 and MDA-MB-231 cells undergo wide-
spread transcriptional changes upon transplantation to
the mammary fat pad, and that the changes in MDA-MB-
231 cells were more profound. This shows that growth in
the in vivo environment of the mammary gland has a con-
siderable impact on the tumor cell transcriptomes andthat the response is cell line-specific. The Gene Ontology
analysis demonstrated that the gene categories represent-
ing extracellular matrix components were enriched among
the genes upregulated in xenografted MCF7 cells, while
the cell adhesion category was enriched in the MDA-MB-
231 cells following transplantation. The difference in re-
sponses in MCF7 and MDA-MB-231 cells is likely not
only affected by which cell line was transplanted but also
by the fact that different transplantation techniques were
used for the two cell types: MDA-MB-231 cells were
transplanted directly into the mammary fat pad whereas
MCF7 cells were grafted into cleared fat pads. Further-
more, the immune status of the recipient mice was differ-
ent: the mice used for MCF7 transplantation were nude
mice, which lack T cells but retain B cells and natural
killer (NK) cells, whereas xenografting of MDA-MB-231
cells was done in SCID mice, which have no T cells and B
cells but retain NK cells. While it is plausible that both the
origin of the transplanted cells, the transplantation tech-
nique and the immune status of the mice contribute to
the profound differences in tumor transcriptomes, the
precise impact of each of these parameters can be ex-
plored by the S3 technology in further studies.
The stromal response to xenografting MCF7 or MDA-
MB-231 cells was also remarkably different, with nearly
4000 genes upregulated in stroma from MCF7 transplants
as compared to MDA-MB-231 transplants. In the PCA,
the genome-wide transcriptome from MCF7 stroma was
intermediate between the MDA-MB-231 and the untrans-
planted stromal transcriptomes. This is in line with the fact
that the basal-type MDA-MB-231 cell line is more aggres-
sive and also produces metastases upon transplantation
[59], but as discussed above the difference in xenografting
techniques and immune status of the mice used for trans-
planting the two cell types is likely to substantially contrib-
ute to the differences in the response. It is interesting to
note that genes upregulated in both the MCF7 and MDA-
MB-231 surrounding stroma include genes involved in
cytokine response as well as several supposedly universal
stromal markers [59], whereas the MCF7 stroma also was
enriched for genes involved in chromatin remodeling.Conclusions
In conclusion, our data from co-cultured cells and xeno-
graft experiments show that the S3 technology allows for
faithful reporting of transcriptomic changes that will
provide new insights from experiments based on mixed-
species cell interactions in vitro or in vivo.Additional files
Additional file 1: Table S1. Fisher’s exact test for count data (R).
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BSA: Bovine serum albumin; CAF: Cancer-associated fibroblast; DAPT: N-[N-
(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester; DLL4: Delta-like
4; DMEM: Dulbecco's modified Eagle medium; DMSO: Dimethyl sulfoxide;
DPBS: Dulbecco's phosphate-buffered saline; FACS: Fluorescence-activated cell
sorting; FDR: False discovery rate; GFP: Green fluorescent protein; HSP: Heat
shock protein; ICD: Intracellular domain; IRES: Internal ribosome entry site;
Luc: Luciferase; NK: Natural killer; PBS: Phosphate-buffered saline; PCA: Principal
component analysis; QC: Quality control; qPCR: Quantitative real-time
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